HUE053429T2 - (S)-3-amino-4-(difluor-metilenil)-ciklopent-l-én-l-karbonsav és rokon vegyületek, mint gaba-aminotranszferáz-inaktivátorok epilepszia, függõség és hepatocelluláris karcinóma kezelésében - Google Patents

(S)-3-amino-4-(difluor-metilenil)-ciklopent-l-én-l-karbonsav és rokon vegyületek, mint gaba-aminotranszferáz-inaktivátorok epilepszia, függõség és hepatocelluláris karcinóma kezelésében

Info

Publication number
HUE053429T2
HUE053429T2 HUE16854531A HUE16854531A HUE053429T2 HU E053429 T2 HUE053429 T2 HU E053429T2 HU E16854531 A HUE16854531 A HU E16854531A HU E16854531 A HUE16854531 A HU E16854531A HU E053429 T2 HUE053429 T2 HU E053429T2
Authority
HU
Hungary
Prior art keywords
difluoromethylenyl
cyclopent
gaba
epilepsy
ene
Prior art date
Application number
HUE16854531A
Other languages
English (en)
Hungarian (hu)
Inventor
Richard Silverman
Kenji Takaya
Hoang Le
Jose Juncosa
Original Assignee
Univ Northwestern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Northwestern filed Critical Univ Northwestern
Publication of HUE053429T2 publication Critical patent/HUE053429T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C229/48Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms of the same non-condensed ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HUE16854531A 2015-10-09 2016-10-10 (S)-3-amino-4-(difluor-metilenil)-ciklopent-l-én-l-karbonsav és rokon vegyületek, mint gaba-aminotranszferáz-inaktivátorok epilepszia, függõség és hepatocelluláris karcinóma kezelésében HUE053429T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562239330P 2015-10-09 2015-10-09

Publications (1)

Publication Number Publication Date
HUE053429T2 true HUE053429T2 (hu) 2021-07-28

Family

ID=58488679

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE16854531A HUE053429T2 (hu) 2015-10-09 2016-10-10 (S)-3-amino-4-(difluor-metilenil)-ciklopent-l-én-l-karbonsav és rokon vegyületek, mint gaba-aminotranszferáz-inaktivátorok epilepszia, függõség és hepatocelluláris karcinóma kezelésében

Country Status (20)

Country Link
US (3) US9670141B2 (OSRAM)
EP (1) EP3341355B1 (OSRAM)
JP (1) JP6841821B2 (OSRAM)
KR (1) KR102745965B1 (OSRAM)
CN (1) CN108137484B (OSRAM)
AU (1) AU2016334396B2 (OSRAM)
BR (1) BR112018007026B1 (OSRAM)
CA (1) CA3001330A1 (OSRAM)
CL (1) CL2018000914A1 (OSRAM)
CO (1) CO2018003828A2 (OSRAM)
DK (1) DK3341355T3 (OSRAM)
ES (1) ES2825349T3 (OSRAM)
HU (1) HUE053429T2 (OSRAM)
IL (1) IL258516A (OSRAM)
LT (1) LT3341355T (OSRAM)
MX (1) MX380592B (OSRAM)
PE (1) PE20190349A1 (OSRAM)
PL (1) PL3341355T3 (OSRAM)
PT (1) PT3341355T (OSRAM)
WO (1) WO2017062942A2 (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20191414T1 (hr) 2014-08-21 2019-11-01 Boehringer Ingelheim Int Novi spojevi i derivati spiro[3h-indol-3,2'-pirolidin]-2(1h)-ona kao mdm1-p53-inhibitori
LT3341355T (lt) * 2015-10-09 2020-11-10 Northwestern University (s)-3-amino-4-(difluormetilenil)ciklopent-1-en-1-karboksirūgštis ir giminingi junginiai kaip gaba aminotransferazės inaktyvatoriai, skirti epilepsijos, priklausomybės ir kepenų ląstelių karcinomos gydymui
HUE054985T2 (hu) 2015-10-09 2021-11-29 Boehringer Ingelheim Int Spiro[3H-indol-3,2'-pirrolidin]-2(1H)-on vegyületek és számrazékok, mint MDM2-P53 inhibitorok
KR20240110989A (ko) 2017-02-08 2024-07-16 오비드 테라퓨틱스 인크. 프라더-윌리 증후군 및 발작 장애들을 치료하는 방법들
KR20240154700A (ko) * 2018-02-08 2024-10-25 오비드 테라퓨틱스 인크. 이명, 급성 감각신경성 난청, 메니에르병, 투렛 증후군, 주의력 결핍 과잉행동 장애 및 중독의 치료에 있어서 (1s,3s)-3-아미노-4-(디플루오로메틸리덴) 시클로펜탄-1-카르복시산 및 (s)-3-아미노-4-(디플루오로메틸리덴)시클로펜트-1-엔-1-카르복시산의 용도
US11771671B2 (en) 2018-02-08 2023-10-03 Ovid Therapeutics Inc. Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder and addiction
WO2019191525A1 (en) * 2018-03-29 2019-10-03 Ovid Therapeutics Inc. Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of eye disorders
US10822301B2 (en) * 2018-04-12 2020-11-03 Northwestern University 3-carbon substituted 4-aminocyclopent-1-ene-1-carboxylic acid compounds as inhibitors of gamma-aminobutyric acid (GABA) aminotransferase
CN117550990B (zh) * 2018-05-25 2025-09-16 西北大学 用于合成(s)-3-氨基-4-(二氟亚甲基)环戊-1-烯-1-甲酸的工艺
KR102744830B1 (ko) 2018-06-07 2024-12-19 오비드 테라퓨틱스 인크. 발달 장애 치료에 있어서, (s)-3-아미노-4-(디플루오로메틸레닐)사이클로펜트-1-엔-1-카르복실산 및 관련된 화합물들, (1s,3s)-3-아미노-4-(디플루오로메틸리덴) 사이클로펜탄 -1-카르복실산 및 비가바트린의 사용
US11203596B2 (en) 2019-02-25 2021-12-21 Northwestern University Analogs of 3-amino-4-(propan-2-ylidene)cyclopentane-1-carboxylic acid and uses thereof for treating diseases and disorders associated with ornithine aminotransferase activity
WO2020206234A1 (en) 2019-04-03 2020-10-08 Northwestern University 2-difluoro substituted 4-aminocyclopentanecarboxylic acids as inhibitors of gamma-aminobutyric acid aminotransferase and human ornithine aminotransferase
CN110935495B (zh) * 2019-11-29 2021-02-23 中国科学院电子学研究所 Gaba和电生理微纳同步传感检测芯片及其制备方法
US11993569B2 (en) 2020-01-23 2024-05-28 Northwestern University 3-amino-4-halocyclopentene carboxylic acids as inactivators of aminotransferases
EP4301724A4 (en) * 2021-03-03 2025-05-28 Northwestern University (S)-3-AMINO-4,4-DIHALOCYCLOPENT-1-CARBOXYLIC ACID AS SELECTIVE INACTIVATORS OF HUMAN ORNITHINE AMINOTRANSFERASE
CA3260997A1 (en) * 2022-07-06 2024-01-11 Ovid Therapeutics Inc. USE OF (S)-3-AMINO-4-(DIFLUOROMETHYLENYL) CYCLOPENT-1-ENE-1-CARBOXYLIC ACID IN CANCER TREATMENT
US20240285563A1 (en) * 2023-02-17 2024-08-29 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of rheumatoid arthritis
KR20250149771A (ko) * 2023-02-17 2025-10-16 오비드 테라퓨틱스 인크. 위장관 장애의 치료 및 면역조절제로서의 (s)-3-아미노-4-(디플루오로메틸레닐)사이클로펜트-1-엔-1-카르복시산의 용도
EP4648797A4 (en) * 2023-02-17 2025-12-24 Ovid Therapeutics Inc USE OF (S)-3-AMINO-4-(DIFLUOROMETHYLENYL)CYCLOPENT-1-ENE-1-CARBOXYLIC ACID IN THE TREATMENT OF MULTIPLE SCLEROSIS
EP4665324A1 (en) * 2023-02-17 2025-12-24 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of diabetes and pre-diabetes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794413B1 (en) * 2002-07-19 2004-09-21 Northwestern University Compounds and related methods for inhibition of γ-aminobutyric acid aminotransferase
IL177609A (en) * 2006-08-21 2015-11-30 Yaron Ilan Use of gobacoline or its analogue to produce a drug to treat liver carcinoma
EP2542234A4 (en) * 2010-02-25 2013-07-31 Univ Northwestern PROCESS FOR USE OF (1S, 3S -) - 3-AMINO-4-DIFLUOROMETHYLENYL-1-CYCLOPENTANIC ACID
AR087700A1 (es) * 2011-08-30 2014-04-09 Gilead Sciences Inc Inhibidores de aldh-2 en el tratamiento de adicciones
LT3341355T (lt) * 2015-10-09 2020-11-10 Northwestern University (s)-3-amino-4-(difluormetilenil)ciklopent-1-en-1-karboksirūgštis ir giminingi junginiai kaip gaba aminotransferazės inaktyvatoriai, skirti epilepsijos, priklausomybės ir kepenų ląstelių karcinomos gydymui

Also Published As

Publication number Publication date
EP3341355A2 (en) 2018-07-04
KR102745965B1 (ko) 2024-12-20
BR112018007026A2 (pt) 2018-10-16
PE20190349A1 (es) 2019-03-07
JP2018531941A (ja) 2018-11-01
CN108137484B (zh) 2021-02-12
ES2825349T3 (es) 2021-05-17
US20180271816A1 (en) 2018-09-27
IL258516A (en) 2018-05-31
MX2018004302A (es) 2018-11-09
US9993449B2 (en) 2018-06-12
LT3341355T (lt) 2020-11-10
EP3341355B1 (en) 2020-09-30
US20170101364A1 (en) 2017-04-13
AU2016334396A1 (en) 2018-04-19
JP6841821B2 (ja) 2021-03-10
HK1253002A1 (zh) 2019-06-06
CL2018000914A1 (es) 2018-08-31
DK3341355T3 (da) 2020-10-26
KR20180052782A (ko) 2018-05-18
WO2017062942A3 (en) 2018-03-01
PT3341355T (pt) 2020-10-21
CO2018003828A2 (es) 2018-07-19
US9670141B2 (en) 2017-06-06
CN108137484A (zh) 2018-06-08
AU2016334396B2 (en) 2021-04-08
CA3001330A1 (en) 2017-04-13
BR112018007026B1 (pt) 2022-06-21
PL3341355T3 (pl) 2021-03-08
WO2017062942A2 (en) 2017-04-13
US20170239202A1 (en) 2017-08-24
MX380592B (es) 2025-03-12
EP3341355A4 (en) 2019-04-10

Similar Documents

Publication Publication Date Title
HUE053429T2 (hu) (S)-3-amino-4-(difluor-metilenil)-ciklopent-l-én-l-karbonsav és rokon vegyületek, mint gaba-aminotranszferáz-inaktivátorok epilepszia, függõség és hepatocelluláris karcinóma kezelésében
DK3334422T3 (da) Anvendelse af cannabidiolsyre i behandling af epilepsi
IL256416A (en) Molecular antigen-binding molecules and their uses
IL259133A (en) Jamkaban combinations for the treatment of cardiovascular disease
ZA201708039B (en) Adenoassociated virus vectors for the treatment of mucopolysaccharidoses
HUE052095T2 (hu) Keratin kezelési készítmények és eljárások
PL3157512T3 (pl) Zastosowanie kannabidioli w leczeniu padaczki
IL254116A0 (en) Treatment of pancreatitis
IL248538B (en) Vector viruses unrelated to the treatment of lysosomal storage disorders
DK3307262T3 (da) Forbindelser til anvendelse ved behandling af neuromuskulære lidelser
GB201500314D0 (en) Pharmaceutical formulations for the treatment of pulmonary arterial hypertension
GB2538181B (en) Improvements relating to the authentication of physical entities
GB201513020D0 (en) Radiation-curable compositions, membranes and the manufacture and use of such membranes
LT3482761T (lt) Kompozicijos, apimančios kromoglicino rūgštį, skirtos dermatito gydymui
GB201513543D0 (en) Compositions for use in the treatment of diabetes
LT3244889T (lt) Farmacinė kompozicija, skirta mikozės gydymui
Belsky The Upside of Vulnerability
Nagy Eight glimpses of Marathon in Scroll 1 of Pausanias
FR3045273B1 (fr) Piquet d'extremite
TH1501007570A (th) เจลที่มีส่วนผสมกรดเอลลาจิกที่มีฤทธิ์ยับยั้งการเพิ่มจำนวนของไวรัส
TH1501004545A (th) องค์ประกอบทางเภสัชกรรมที่มีเด็กซ์คีโตโพรเฟนและทรามาดอล
TH1501004118A (th) สารกระทำสำหรับการเพิ่มระดับความเข้มข้นของไนตริกออกไซด์
TH159572S (th) อุปกรณ์เชื่อมต่อรางน้ำ
TH59904S1 (th) อุปกรณ์เชื่อมต่อรางน้ำ